ECCO 2019 - The 14th Congress of ECCO highlighted current trends in patient management and best practices for treating patients with IBD. Watch expert faculty provide valuable insight on key issues during the Takeda sponsored satellite symposia on both Crohn’s disease and ulcerative colitis.
UEG Week 2018 - Watch key presentations from the Takeda sponsored satellite symposia that focused on achieving rapid and sustained efficacy in IBD therapies across both Crohn’s disease and ulcerative colitis.
The growing understanding of the immunopathogenesis of inflammatory bowel disease (IBD) has provided a variety of novel therapeutic targets. Apart from the tumour necrosis factor-α mediated pathway, which is the target of the first marketed biologics in this indication, several other pathways are involved in triggering an inflammatory response.
In both ulcerative colitis and Crohn’s disease, the invasion of the intestinal mucosa by leukocytes is now an important clinical focus (Park & Jeen, 2018). Anti-integrin therapies which block the action of integrins and endothelial cell adhesion molecules include natalizumab and also vedolizumab which targets trafficking of leukocytes. Find out more about their mechanisms of action, explore the relevant study data and review recent data shared at Congresses.
What role do integrins play in IBD? Why would targeting this pathway be an attractive treatment option?
Anti-integrin-based therapeutics have been demonstrated to be efficacious in both ulcerative colitis and Crohn’s disease. Find out the relevant clinical trial data for ulcerative colitis and Crohn’s disease.
Want to know more about what’s going on in IBD? This key events and meetings section can help you keep up-to-date.